A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 305 participants.
Also called NCT04669041
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 305 participants
- Sponsor
- Registry
-
NCT04669041
-
- Other papers using this trial's data
- Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04669041. Randomized; triple masking; primary purpose treatment. Start 2020-12-08 (actual); primary completion 2022-06-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy
- Acronym
- ROZEL
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- SPC ezetimibe/rosuvastatin
- Intervention (Drug)
- Rosuvastatin active capsule
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Placebo
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct04669041- Content hash
089280f0b73e2f5bc8e06538b96b0e03b7afa6cde6c0209088b784395ee95401